LRIG1 and melanoma: Additionally, erlotinib also antagonized LRIG1 knockdown-induced decrease in E-cadherin and increase in vimentin in hypoxia-stimulated melanoma cells, indicating that LRIG1 depression could enhance hypoxia-induced EMT by activating the EGFR/ERK pathway.